Please login to the form below

Not currently logged in
Email:
Password:

Gilead, Merck get CHMP backing for new hep C combinations

Approval of Epclusa and Zepatier will see the pan-genotypic drugs compete for market share
Gilead Sciences

Competition looks set to heat up the EU hepatitis C virus (HCV) market after two new therapies received the go-ahead from the Committee for Medicinal Products for Human Use (CHMP).

Gilead Sciences and Merck Sharp & Dohme (MSD) both bagged CHMP positive opinions for two-drug, once-daily combinations for treating adults with chronic HCV - Epclusa (sofosbuvir/velpatasvir) and Zepatier (elbasvir/grazoprevir), respectively.

For Gilead, this is the first regulatory okay for Epclusa, a follow-up to its Sovaldi (sofosbuvir) and Harvoni (sofosbuvir/ledipasvir) products that currently dominate the HCV market with sales of $5.3bn and $10bn last year.

The company is positioning Epclusa as a pan-genotypic regimen that will treat all different HCV genotypes (1-6), doing away with the need for genotyping before the start of treatment. It is also under priority review in the US and could be approved there by the end of next month.

Meanwhile, the positive opinion for Zepatier means MSD is now weeks away from having approval on both sides of the Atlantic for Zepatier as it tries to wrest market share away from Gilead, with the FDA approving the drug in January for HCV genotypes 1 and 4.

"Epclusa and Zepatier belong to a new generation of medicines for chronic HCV infection, direct-acting antivirals, that give high rates of cure of HCV infection," said the CHMP.

In the past few years these drugs have "reshaped the way this disease is treated", it added, allowing patients to be cured without the use of injectable and hard-to-tolerate interferon drugs.

At its meeting last week the CHMP also gave a green light to AstraZeneca's DPP-4 inhibitor/SGLT2 inhibitor combination Qtern (saxagliptin/dapagliflozin) as a treatment for type 2 diabetes. The positive verdict for the product is a boost to AZ as it was turned down by the US FDA last October.

Bad news for Takeda
There was disappointment for Takeda, however, after the CHMP rejected its application to market its orally-active proteasome inhibitor Ninlaro (ixazomib) as a treatment for multiple myeloma. The drug - the first oral drug in the class - was approved by the FDA last November.

The committee said data from the main study filed in support of the drug were insufficient to demonstrate a benefit of the drug in a hard-to-treat patient group who had previously received one or more prior therapies.

Article by
Phil Taylor

31st May 2016

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics